Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II

View this table:

[in a new window]

Table 1. Comparison of Baseline Clinical Characteristics of the Duke Medical Therapy Group and Patients in the Multicenter Automatic Defibrillator Implantation Trial-II

View larger version (21K):

[in a new window]

Figure 1. Survival comparison of patients in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II with patients in the Duke medical therapy and implantable cardioverter defibrillator (ICD) groups. The estimated survival curves for the Duke medical therapy and ICD groups were adjusted to reflect a more recent era of ischemic heart disease and heart failure management (1998–2001).

View larger version (19K):

[in a new window]

Figure 2. Survival projections for implantable cardioverter defibrillator (ICD) therapy versus medical therapy.

View this table:

[in a new window]

Table 2. Clinical Events, Survival, and Medical Costs for the Duke Medical Therapy Group

View this table:

[in a new window]

Table 3. Costs for Placement of Implantable Cardioverter Defibrillators, Follow-up, Maintenance, and Complications

View this table:

[in a new window]

Table 4. Projected Survival and Medical Costs for the Duke Medical Therapy Group and the Duke Implantable Cardioverter Defibrillator Group

View this table:

[in a new window]

Table 5. Results of Base-Case Analysis

View this table:

[in a new window]

Table 6. Results of One-Way Sensitivity Analysis

View larger version (24K):

[in a new window]

Figure 3. Cost-effectiveness of implantable cardioverter defibrillator (ICD) therapy versus medical therapy. ICER = incremental cost-effectiveness ratio.